Dermatitis News

WAILEA, Hawaii — A proof-of-concept study of ASLAN004 found it to be safe and efficacious in treating moderate to severe atopic dermatitis, according to a poster presented at Maui Derm for Dermatologists.

Adults with moderate-to-severe atopic dermatitis treated with dupilumab had fewer and shorter hospitalizations related to the skin condition, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

WAILEA, Hawaii — Atopic dermatitis of the head and neck was improved in patients treated with lebrikizumab, according to a study presented at Maui Derm for Dermatologists.

The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.

The FDA approved Rinvoq, a selective JAK inhibitor, for the treatment of moderate to severe atopic dermatitis among patients aged 12 years and older, according to a press release.

The FDA approved many new drugs and technologies over the past year, and in the dermatology world those approvals included treatments for a multitude of conditions.

Women with a history of asthma, atopic dermatitis and allergic rhinitis before conception demonstrated increased risk for peripartum mental disorders, according to a study published in Clinical and Translational Allergy.

The FDA has approved tralokinumab for the treatment of moderate to severe atopic dermatitis, LEO Pharma announced in a press release.

Both children and adults with atopic dermatitis showed disease improvement with minimal adverse outcomes after using a Staphylococcus aureus-based topical treatment, according to a study.

Eli Lilly reported lebrikizumab was safe and efficacious in improving moderate to severe atopic dermatitis in combination with topical corticosteroids in the company’s third phase 3 ADhere trial, according to a company press release.